Abstract
Introduction: The burden of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is increasing worldwide. This phenomenon poses a potentially dangerous risk of rise in mortalities caused by cirrhosis and liver cancer. Owing to a complex combination of factors, NAFLD and NASH arise in a majority of people living with HIV (PLWH), but accurate estimates of prevalence differ, depending on sample selection, type of analysis, and data interpretation. The wide range of diagnostic tools used to assess liver steatosis and lack of control groups in many studies further contributes to current difficulties in properly assessing prevalence of these conditions. Areas covered: Thoroughly scrutinizing the current literature, we compared the prevalence of NAFLD and NASH in PLWH to rates found in the general population. We highlighted strengths and limitations of the studies, in order to determine the effective impact of these medical conditions in PLWH. Expert opinion: The prevalence and progression of NAFLD in human immunodeficiency virus (HIV) infection are reported to be widely variable. HIV infection itself and antiretroviral treatment have been demonstrated to play a role in the development of NAFLD. Larger and more effective studies are needed to evaluate the effects of NASH in PLWH and its progression.
| Original language | English |
|---|---|
| Pages (from-to) | 643-650 |
| Number of pages | 8 |
| Journal | Expert Review of Gastroenterology and Hepatology |
| Volume | 13 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 3 2019 |
Fingerprint
Keywords
- Antiretroviral therapy
- hepatic steatosis
- HIV
- nonalcoholic fatty liver disease
- nonalcoholic steatohepatitis
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
Cite this
Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV. / Squillace, Nicola; Soria, Alessandro; Bozzi, Giorgio; Gori, Andrea; Bandera, Alessandra.
In: Expert Review of Gastroenterology and Hepatology, Vol. 13, No. 7, 03.07.2019, p. 643-650.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV
AU - Squillace, Nicola
AU - Soria, Alessandro
AU - Bozzi, Giorgio
AU - Gori, Andrea
AU - Bandera, Alessandra
PY - 2019/7/3
Y1 - 2019/7/3
N2 - Introduction: The burden of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is increasing worldwide. This phenomenon poses a potentially dangerous risk of rise in mortalities caused by cirrhosis and liver cancer. Owing to a complex combination of factors, NAFLD and NASH arise in a majority of people living with HIV (PLWH), but accurate estimates of prevalence differ, depending on sample selection, type of analysis, and data interpretation. The wide range of diagnostic tools used to assess liver steatosis and lack of control groups in many studies further contributes to current difficulties in properly assessing prevalence of these conditions. Areas covered: Thoroughly scrutinizing the current literature, we compared the prevalence of NAFLD and NASH in PLWH to rates found in the general population. We highlighted strengths and limitations of the studies, in order to determine the effective impact of these medical conditions in PLWH. Expert opinion: The prevalence and progression of NAFLD in human immunodeficiency virus (HIV) infection are reported to be widely variable. HIV infection itself and antiretroviral treatment have been demonstrated to play a role in the development of NAFLD. Larger and more effective studies are needed to evaluate the effects of NASH in PLWH and its progression.
AB - Introduction: The burden of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) is increasing worldwide. This phenomenon poses a potentially dangerous risk of rise in mortalities caused by cirrhosis and liver cancer. Owing to a complex combination of factors, NAFLD and NASH arise in a majority of people living with HIV (PLWH), but accurate estimates of prevalence differ, depending on sample selection, type of analysis, and data interpretation. The wide range of diagnostic tools used to assess liver steatosis and lack of control groups in many studies further contributes to current difficulties in properly assessing prevalence of these conditions. Areas covered: Thoroughly scrutinizing the current literature, we compared the prevalence of NAFLD and NASH in PLWH to rates found in the general population. We highlighted strengths and limitations of the studies, in order to determine the effective impact of these medical conditions in PLWH. Expert opinion: The prevalence and progression of NAFLD in human immunodeficiency virus (HIV) infection are reported to be widely variable. HIV infection itself and antiretroviral treatment have been demonstrated to play a role in the development of NAFLD. Larger and more effective studies are needed to evaluate the effects of NASH in PLWH and its progression.
KW - Antiretroviral therapy
KW - hepatic steatosis
KW - HIV
KW - nonalcoholic fatty liver disease
KW - nonalcoholic steatohepatitis
UR - http://www.scopus.com/inward/record.url?scp=85067625430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067625430&partnerID=8YFLogxK
U2 - 10.1080/17474124.2019.1614913
DO - 10.1080/17474124.2019.1614913
M3 - Review article
C2 - 31081390
AN - SCOPUS:85067625430
VL - 13
SP - 643
EP - 650
JO - Expert Review of Gastroenterology and Hepatology
JF - Expert Review of Gastroenterology and Hepatology
SN - 1747-4124
IS - 7
ER -